⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
businesswire.com
TAK
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
globenewswire.com
INCY
ACRS
TAK
AZN
PFE
GSK
JNJ
NVS
SNY
BHC
REGN
ABBV
ALGN
BMY
AMGN
ARCT
CANF
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
prnewswire.com
BIIB
TAK
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
businesswire.com
TAK
United States Personalized Medicine Market - Genomic Trends, Size, Share, and Forecast 2026-2034 | AI, NGS, and Targeted Therapies Propel Growth to US$327.97 Billion
globenewswire.com
ABT
GEHC
ILMN
QGEN
LLY
TAK
ABBV
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication
businesswire.com
TAK
Takeda presenta en ESID 2026 los resultados del estudio IgGNITE de fase 2/3 de TAK-881, una terapia subcutánea en investigación para la inmunodeficiencia primaria (IDP)
businesswire.com
TAK
Takeda stellt auf der ESID 2026 Ergebnisse der Phase-2/3-Studie IgGNITE zu TAK-881 vor, einem Prüfpräparat zur subkutanen Behandlung primärer Immundefekte (PID)
businesswire.com
TAK
Takeda apresenta resultados do estudo de fase 2/3 IgGNITE do TAK-881 subcutâneo experimental para imunodeficiência primária (IDP) na ESID 2026
businesswire.com
TAK
Takeda在2026年歐洲免疫缺陷學會發表為原發性免疫缺陷症 (PID) 患者注射研發中皮下注射藥物TAK-881的二/三期IgGNITE研究結果
businesswire.com
TAK